Best Practice in Innovation, Entrepreneurship & Design
Join us for the fifth encounter in the series:
29 June 2010, 17.30 to 19.00
Attracting the technology buyer: How large firms source innovations
Panellists:
- Prof. Ammon Salter – Reader in Innovation Management, Imperial College Business School
- Dr. Mike Addison – New Business Development Manager, Corporate R&D, Procter & Gamble
- Dr. Chris Newton – Senior Vice President, BioFocus
- John Burt – Co-founder and former CEO, Thiakis
Many large firms are increasingly looking to external sources to help them innovate. Some organisations, such as P&G, Pfizer and NovoNordisk, have explicit targets of the share of their innovations that should come form external sources. However, many large firms still find it difficult to utilise these external ideas. This session will explore how small firms and inventors can shape their ideas for use by large firms, examining the types of IP that facilitate the exchange and what types of financial arrangements provide for fair risk and reward sharing for both parties. It will also explore the challenges for small firms and inventors of working with a large partner in trying to successfully commercialise a new idea.
Hear our panel’s views and offer your own. A reception of wine and canapés will follow the event.
About the panel:
Prof. Ammon Salter – Reader in Innovation Management, Imperial College Business School
Prof. Ammon Salter is a Reader and co-Director of the Innovation Studies Centre at Imperial College Business School. Additionally, he is Research Director of the UK Innovation Research Centre (UK~IRC) and also a Fellow of the Advanced Institute of Management Research (AIM). His main research interest is the management of technological innovation, examining how organisations can harness external networks to help innovate more successfully. His latest paper published in MIT Sloan Management Review focuses on how firms can find the right balance between open innovation and intellectual property. He has also published over 30 refereed journal articles and three books.
Dr. Mike Addison – New Business Development Manager, Corporate R&D, Procter & Gamble
Dr. Mike Addison has been with Procter & Gamble’s European Research & Development department for almost 28 years. Throughout his career, he has managed all the major R&D roles required to develop and deliver new products to market for a number of P&G businesses. For 3 years he was in charge of a $1Million Innovation Seed fund to stimulate innovation across the European R&D organisations. Mike has also been involved with P&G’s Connect + Develop (or Open Innovation) strategy, searching for external new business opportunities, in which P&G may play an important role helping to commercialise or realise their full value in the marketplace.
Dr. Chris Newton – Senior Vice President, BioFocus
Dr. Chris Newton is responsible for all operational and commercial activities at BioFocus, whose parent company, Galapagos, has an alliance with GlaxoSmithKline CEEDD (Centre of Excellence for External Drug Discovery). Previously he was a founding scientist, CSO and Board Director at Argenta Discovery Ltd. He has held a variety of senior management positions in both research and development in the Rhone-Poulenc group of companies, delivering a number of clinical programs and one marketed drug. Chris holds an MA in Natural Sciences from the University of Cambridge (Emeleus chemistry prize holder) and a PhD from the University of Sheffield (Turner Prize holder). Chris is the author and inventor of over 50 publications and patents relating to new drug discovery.
John Burt – Co-founder and former CEO, Thiakis
John Burt co-founded and led Thiakis through to its £100 million sale to Wyeth Pharmaceuticals, delivering a significant return to investors. Thiakis sourced its intellectual property from Imperial Innovations, and executed a licence agreement with US drug delivery company, Nastech. Prior to this, John held a range of finance and business development roles – notably with Vernalis, GlaxoSmithKline and Imperial Innovations – executing research collaborations, licences and corporate transactions. Notable deals include the research framework for the GSK Clinical Imaging Centre, a strategic academic drug discovery alliance for Imperial College, the spin-out of Affymax from GSK in 2001, and many outsourced contract research agreements.
Location:
LTUG, Upper Ground Floor Lecture Theatre
Imperial College Business School
Tanaka Building
South Kensington Campus
Exhibition Road
London SW7 2AZ
Further information:
The series is organised by The Entrepreneurship Hub at Imperial College Business School and is supported by the Higher Education Innovation Fund (HEIF).
Click here for further information and dates of other events in the Best Practice series.
Contact details:
E: entrepreneurship@imperial.ac.uk
T: +44 (0) 20 7594 1438
W: www.imperial.ac.uk/entrepreneurship